DHFR Inhibitors: Reading the Past for Discovering Novel Anticancer Agents.


Journal

Molecules (Basel, Switzerland)
ISSN: 1420-3049
Titre abrégé: Molecules
Pays: Switzerland
ID NLM: 100964009

Informations de publication

Date de publication:
22 Mar 2019
Historique:
received: 25 02 2019
revised: 18 03 2019
accepted: 20 03 2019
entrez: 27 3 2019
pubmed: 27 3 2019
medline: 16 7 2019
Statut: epublish

Résumé

Dihydrofolate reductase inhibitors are an important class of drugs, as evidenced by their use as antibacterial, antimalarial, antifungal, and anticancer agents. Progress in understanding the biochemical basis of mechanisms responsible for enzyme selectivity and antiproliferative effects has renewed the interest in antifolates for cancer chemotherapy and prompted the medicinal chemistry community to develop novel and selective human DHFR inhibitors, thus leading to a new generation of DHFR inhibitors. This work summarizes the mechanism of action, chemical, and anticancer profile of the DHFR inhibitors discovered in the last six years. New strategies in DHFR drug discovery are also provided, in order to thoroughly delineate the current landscape for medicinal chemists interested in furthering this study in the anticancer field.

Identifiants

pubmed: 30909399
pii: molecules24061140
doi: 10.3390/molecules24061140
pmc: PMC6471984
pii:
doi:

Substances chimiques

Antineoplastic Agents 0
Folic Acid Antagonists 0
Folic Acid 935E97BOY8
Tetrahydrofolate Dehydrogenase EC 1.5.1.3

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Ministero dell'Istruzione, dell'Università e della Ricerca
ID : PJ_RIC_FFABR_2017_160599

Références

J Mol Biol. 2002 Jul 12;320(3):677-93
pubmed: 12096917
Am J Med Sci. 1951 Feb;221(2):176-82
pubmed: 14799481
Arthritis Rheum. 2004 May;50(5):1370-82
pubmed: 15146406
Nat Rev Drug Discov. 2004 Jun;3(6):509-20
pubmed: 15173840
N Engl J Med. 2005 Apr 14;352(15):1565-77
pubmed: 15829537
Trop Med Int Health. 2005 Aug;10(8):723-33
pubmed: 16045458
J Nat Prod. 2007 Apr;70(4):689-710
pubmed: 17362037
Protein Sci. 2007 Jun;16(6):1087-100
pubmed: 17473015
Protein Expr Purif. 2008 Nov;62(1):104-10
pubmed: 18672067
Biochemistry. 2008 Sep 2;47(35):9227-33
pubmed: 18690714
N Engl J Med. 1948 Jun 3;238(23):787-93
pubmed: 18860765
Mutat Res. 2009 Feb 19;673(1):43-52
pubmed: 19110071
J Am Chem Soc. 2009 Apr 22;131(15):5642-7
pubmed: 19323547
J Med Chem. 1991 Feb;34(2):479-85
pubmed: 1995868
J Phys Chem B. 2011 Feb 24;115(7):1616-22
pubmed: 21287995
Cancer Manag Res. 2010 Nov 19;2:293-301
pubmed: 21301589
FASEB J. 1990 May;4(8):2441-52
pubmed: 2185970
Nat Rev Drug Discov. 2011 Aug 31;10(9):671-84
pubmed: 21878982
Eur Respir J. 2013 Aug;42(2):504-12
pubmed: 23100498
Mol Pharmacol. 2013 Feb;83(2):339-53
pubmed: 23197646
Eur J Med Chem. 2013 May;63:33-45
pubmed: 23454532
PLoS One. 2013;8(4):e60470
pubmed: 23577115
Eur J Med Chem. 2013 Aug;66:135-45
pubmed: 23792351
Medchemcomm. 2013 Sep 1;4(9):1275-1282
pubmed: 24163729
Eur J Med Chem. 2014 Mar 3;74:234-45
pubmed: 24469112
Eur J Med Chem. 2014 Mar 3;74:440-50
pubmed: 24487192
Biochem Pharmacol. 2014 Aug 1;90(3):226-34
pubmed: 24875448
Bioorg Med Chem Lett. 2014 Sep 15;24(18):4557-4567
pubmed: 25139568
Dalton Trans. 2015 Feb 21;44(7):3043-56
pubmed: 25567238
Cell. 2015 Dec 3;163(6):1297-300
pubmed: 26638061
Bioorg Med Chem Lett. 2016 Jan 15;26(2):518-523
pubmed: 26670841
Eur J Med Chem. 2016 Jun 10;115:63-74
pubmed: 26994844
Oncol Lett. 2016 Jun;11(6):3863-3869
pubmed: 27313708
Bioorg Med Chem Lett. 2016 Oct 1;26(19):4815-4823
pubmed: 27554444
Eur J Med Chem. 2017 Jan 5;125:1279-1288
pubmed: 27886545
Eur J Med Chem. 2017 Mar 10;128:88-97
pubmed: 28152430
J Med Chem. 2017 Mar 9;60(5):1734-1745
pubmed: 28177228
Bioorg Chem. 2017 Jun;72:282-292
pubmed: 28499189
Bioinformation. 2017 Mar 31;13(3):63-66
pubmed: 28584445
J Biol Chem. 2017 Aug 25;292(34):14229-14239
pubmed: 28620051
Eur J Med Chem. 2017 Sep 29;138:630-643
pubmed: 28711701
Bioorg Chem. 2017 Oct;74:228-237
pubmed: 28865294
Nanomaterials (Basel). 2018 Jan 04;8(1):null
pubmed: 29300349
Bioorg Med Chem. 2018 May 15;26(9):2674-2685
pubmed: 29691154
Bioorg Chem. 2018 Oct;80:11-23
pubmed: 29864684
Med Res Rev. 2019 Mar;39(2):684-705
pubmed: 30192413
J Am Chem Soc. 2018 Dec 5;140(48):16650-16660
pubmed: 30398861
Adv Enzyme Regul. 1994;34:397-419
pubmed: 7942284
Oncology (Williston Park). 1995 Jul;9(7):649-56, 659 DISC 660, 662, 665
pubmed: 8924375
Biochemistry. 1997 Jan 21;36(3):586-603
pubmed: 9012674
Proc Natl Acad Sci U S A. 1997 Apr 1;94(7):3290-5
pubmed: 9096386
Br J Cancer. 1998;78 Suppl 3:1-7
pubmed: 9717984

Auteurs

Maria Valeria Raimondi (MV)

Department of Biological, Chemical and Pharmaceutical Sciences and Technologies (STEBICEF), University of Palermo, via Archirafi 32, 90123 Palermo, Italy. mariavaleria.raimondi@unipa.it.

Ornella Randazzo (O)

Department of Biological, Chemical and Pharmaceutical Sciences and Technologies (STEBICEF), University of Palermo, via Archirafi 32, 90123 Palermo, Italy. ornella.randazzo01@unipa.it.

Mery La Franca (M)

Department of Biological, Chemical and Pharmaceutical Sciences and Technologies (STEBICEF), University of Palermo, via Archirafi 32, 90123 Palermo, Italy. mery.lafranca@unipa.it.

Giampaolo Barone (G)

Department of Biological, Chemical and Pharmaceutical Sciences and Technologies (STEBICEF), University of Palermo, via Archirafi 32, 90123 Palermo, Italy. giampaolo.barone@unipa.it.

Elisa Vignoni (E)

Drug Sciences Department, Medicinal Chemistry and Pharmaceutical Technology Section, University of Pavia, via Taramelli 12, 27100 Pavia, Italy. elisa.vignoni01@universitadipavia.it.

Daniela Rossi (D)

Drug Sciences Department, Medicinal Chemistry and Pharmaceutical Technology Section, University of Pavia, via Taramelli 12, 27100 Pavia, Italy. daniela.rossi@unipv.it.

Simona Collina (S)

Drug Sciences Department, Medicinal Chemistry and Pharmaceutical Technology Section, University of Pavia, via Taramelli 12, 27100 Pavia, Italy. simona.collina@unipv.it.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH